Randomized Trialhigh evidence
Hydralazine-isosorbide dinitrate in chronic heart failure with reduced ejection fraction: the H-HeFT trial.
European heart journal·November 4, 2026·PMID 42978512
Why it mattersDespite prior evidence of benefit in selected populations, H-ISDN did not improve outcomes in a broad contemporary HFrEF cohort, challenging its routine use in this setting.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled